Drug intelligence / Profile preview

Car1

Development stage: Preclinical
Lead developer: NemaGen Discoveries
Modality: Small Molecules
Administration: Oral

Overview

Car1 is a preclinical-stage small molecule developed by NemaGen Discoveries that targets carbonic anhydrase 1 (CA1). It is being investigated for the treatment of allergic inflammation, mastocytosis, and other mast cell-related diseases. Carbonic anhydrases are enzymes that catalyze the reversible hydration of carbon dioxide; CA1 specifically has been implicated in the regulation of mast cell activation and inflammatory responses. By modulating CA1 activity, this therapeutic candidate aims to alleviate symptoms and underlying pathology in conditions driven by mast cell dysfunction.

Targets

CA1 (Carbonic anhydrase 1)

Beyond the preview

Go deeper on Car1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Car1.

Explore the full profile